Shots:
- Pfizer to sponsor & conduct P-Ib/II study evaluating the safety, tolerability, and preliminary efficacy of dual regimen and will assume costs of study & other expenses related to IP rights. The companies will form a joint development committee to manage clinical study which is anticipated to commence in H1’21
- The focus of the collaboration is to evaluate SpringWorks’ Nirogacestat + Pfizer’s PF‐06863135, in patients with r/r MM. Additionally, SpringWorks is currently conducting a global P-III DeFi trial to evaluate nirogacestat in adults with progressing desmoid tumors
- Nirogacestat is investigational, oral, selective, small-molecule GSI in P-III while PF‐06863135 is anti-BCMA CD3 bispecific Ab (SC), being investigated in P-I study to treat r/r MM
Click here to read full press release/ article | Ref: PRNewswire | Image: Solar Winds MSP
The post Pfizer Signs an Agreement with SpringWorks to Evaluate Nirogacestat + PF‐06863135 for R/R Multiple Myeloma first appeared on PharmaShots.
